Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IMG-1
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : IP Investors LLC
Deal Size : $32.5 million
Deal Type : Series A Financing
Details : The net proceeds will be used to advance the company's priority programs in regenerative medicine, oral delivery, and therapeutics and for the continued development of its novel IMG-1 polypeptide.
Product Name : IMG-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 31, 2023
Lead Product(s) : IMG-1
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : IP Investors LLC
Deal Size : $32.5 million
Deal Type : Series A Financing